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The role of serum procalcitonin in
establishing the diagnosis and prognosis of
pleural infection
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Abstract
Background: Bacterial pleural infection requires prompt identification to enable appropriate investigation and
treatment. In contrast to commonly used biomarkers such as C-reactive protein (CRP) and white cell count (WCC),
which can be raised due to non-infective inflammatory processes, procalcitonin (PCT) has been proposed as a
specific biomarker of bacterial infection. The utility of PCT in this role is yet to be validated in a large prospective
trial. This study aimed to identify whether serum PCT is superior to CRP and WCC in establishing the diagnosis of
bacterial pleural infection.
Methods: Consecutive patients presenting to a tertiary pleural service between 2008 and 2013 were recruited to a
well-established pleural disease study. Consent was obtained to store pleural fluid and relevant clinical information.
Serum CRP, WCC and PCT were measured. A diagnosis was agreed upon by two independent consultants after a
minimum of 12 months. The study was performed and reported according to the STARD reporting guidelines.
Results: 80/425 patients enrolled in the trial had a unilateral pleural effusion secondary to infection. 10/80 (12.5%)
patients had positive pleural fluid microbiology. Investigations for viral causes of effusion were not performed. ROC
curve analysis of 425 adult patients with unilateral undiagnosed pleural effusions showed no statistically significant
difference in the diagnostic utility of PCT (AUC 0.77), WCC (AUC 0.77) or CRP (AUC 0.85) for the identification of
bacterial pleural infection. Serum procalcitonin >0.085 μg/l has a sensitivity, specificity, negative predictive value
and positive predictive value of 0.69, 0.80, 0.46 and 0.91 respectively for the identification of pleural infection. The
diagnostic utility of procalcitonin was not affected by prior antibiotic use (p = 0.80).
Conclusions: The study presents evidence that serum procalcitonin is not superior to CRP and WCC for the
diagnosis of bacterial pleural infection. The study suggests routine procalcitonin testing in all patients with
unilateral pleural effusion is not beneficial however further investigation may identify specific patient subsets that
may benefit.
Trial registration: The trial was registered with the UK Clinical Research Network (UKCRN ID 8960). The trial was
approved by the South West Regional Ethics Committee (Ethical approval number 08/H0102/11).
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Background
Infection is a common cause of undiagnosed unilateral
pleural effusion associated with high morbidity and mor-
tality [1]. The ability to identify bacterial pleural infec-
tion in adults (hereon referred to as “pleural infection”)
as the likely cause at presentation enables appropriate
investigations and prompt treatment [2, 3]. In addition,
this would ensure patients receive prompt inpatient
treatment for pleural infection rather than undergo in-
vestigations for alternative pathologies such as suspected
pleural malignancy.
Pleural infection may be indicated by symptomatology,
classical radiological findings, positive blood culture,
raised inflammatory markers, pleural fluid cytology or
positive pleural fluid microbiology [1]. However, com-
monly used serum biomarkers such as C-reactive protein
(CRP) and white cell count (WCC) are well known to be
general markers of pro-inflammatory states. Further-
more, pleural fluid culture is negative in up to 40% of
samples in patients with classical symptoms and signs
[2]. Pleural fluid pH, lactate dehydrogenase (LDH) and
glucose have been shown to be superior to these
commonly used biomarkers in identifying pleural infec-
tion [4]. Novel biomarkers found in blood and pleural
fluid such as procalcitonin (PCT), soluble triggering
receptor expressed on myeloid cells (sTREM) and
lipopolysaccharide-binding protein (LBP) have been
studied to determine their clinical utility in pleural effu-
sions with mixed and conflicting results [5–7].
Procalcitonin has been proposed as a specific sys-
temic marker of bacterial infection which is not af-
fected by viral and other non-bacterial inflammatory
states [8]. Previous research has attempted to clarify
the role of serum and pleural fluid PCT in identifying
patients with pleural infection [5, 6]. Pleural fluid
PCT has been shown to have no clinical use in
pleural infection diagnosis or prognosis [6]. Lee et al.
have previously presented data suggesting serum PCT
may have a role in differentiating parapneumonic ef-
fusions from malignant effusions [7]. However, an-
other small study suggested serum procalcitonin does
not help differentiate benign from malignant aetiol-
ogies [9]. Whilst procalcitonin is unlikely to remove
the requirement for pleural fluid sampling it is yet to
be determined whether serum PCT has a role as a
first-line investigation in clinical practice.
This main objective of the study was to determine
whether PCT is superior to white cell count and C-
reactive protein when distinguishing between pleural in-
fection and other causes of unilateral pleural effusion in
adults. The secondary objectives of the article were; 1)
Does the prior use of antibiotics affect the utility of PCT
in the diagnosis of unilateral pleural effusion? 2) Does a
high PCT level indicate a poorer outcome in pleural
infection or help predict the need for surgical interven-
tion in patients with pleural infection? 3) Does PCT have
a role in identifying patients with malignancy and a co-
existing infection?
Methods
Consecutive patients presenting to a single specialist
adult tertiary pleural service with a pleural effusion were
invited to consent to a prospective study between March
2008 and June 2013. All patients who consented to re-
cruitment were included in the initial stages of the study.
Radiographic (chest xray) and ultrasound appearances
were used to select patients with unilateral effusions.
The study received ethical approval from the South
West regional ethics committee (Ethical approval num-
ber 08/H0102/11) and was registered with the UK
Clinical Research Network (UKCRN ID 8960). All pa-
tients provided informed written consent to take part in
the study. A full history was obtained, clinical examin-
ation was performed and blood samples were taken at
the time of presentation. Clinical details were collected
and blood and pleural fluid samples were stored. Further
investigation was performed according to national guide-
lines [10]. Venous blood samples were allowed to clot at
room temperature and centrifuged at 1000 g. The super-
natant was then stored at −80 °C. The hospital pathology
department undertook all blood tests except PCT.
Baseline serum PCT was measured on stored samples by
a commercially available enzyme-linked fluorescent
assay as per the manufacturer’s instructions by GD, ALL,
AJM and CEH (Vidas® BRAHMS PCT – BioMerieux).
The assay was unable to detect PCT at levels less than
0.05 μg/l.
Antibiotic use, the need for invasive intervention, dur-
ation of hospital stay and mortality was recorded. The
decision for invasive intervention including chest tube
drainage was determined according to national guide-
lines [1]. Indications for chest tube drainage included
frank pus on aspiration, positive pleural fluid microbiol-
ogy and pleural pH <7.2 [1]. Patients with sepsis in asso-
ciation with a pleural collection despite chest tube
drainage and antibiotics were referred to thoracic sur-
gery. Thoracic surgery was carried out according to an
experienced multi-disciplinary team acting on an indi-
vidual patient basis. All patients had a definitive diagno-
sis independently verified by two consultant physicians
after a minimum of 12 months of follow up. In case of
disagreement a consensus was established through re-
appraisal of relevant investigations. Follow up at
12 months was used to allow for patients who required
interval investigations to confirm the diagnosis. Patients
were classified into diagnostic categories according to
pre-defined criteria (see Additional file 1: Full diagnostic
criteria). All data except the PCT value were available
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during investigation and treatment. Additionally, each
consultant confirming the diagnosis had all clinical in-
formation except for the PCT value.
Statistical analysis including Receiver Operator
Characteristics (ROC) analyses were performed using
SPSS (IBM, Chicago, IL, USA). A p-value of <0.05
was considered to indicate statistical significance. The
optimal cut-off values were determined for the diag-
nostic and prognostic ability of PCT, WCC and CRP
by calculating the combined sensitivity and specificity
for each value using SPSS. The highest combined sen-
sitivity and specificity was chosen as the cut-off value.
There was no hierarchy between sensitivity and specificity.
The cut-off value of <0.05 μg/l was also analysed when
PCT was used to indicate infection. Independent samples
T-test was used to compare PCT, WCC and CRP in cer-
tain patient subsets.
The study used the STARD reporting guidelines (see
Additional file 2: STARD reporting guidelines) [11].
Results
Study population demographics
Five hundred and eight patients with a unilateral pleural
effusion were recruited. 432 patients had a complete
data set available for analysis. Full results were unavail-
able for 76 (15.0%) patients due to inadequate sample
storage. The diagnoses of these patients can be found in
Table 1. A definitive diagnosis could not be established
for 7 patients (1.4%). Therefore 425 (83.7%) patients
were analysed in this study (Fig. 1). The median age and
interquartile range, sex ratio, patient setting and diagno-
sis for all 508 patients can be found in Table 1. The 12-
month diagnoses of the 425 patients analysed in the
study along with the median PCT, WCC and CRP with
interquartile range can be found in Table 2.
Eighty patients had a 12-month diagnosis of effusion
secondary to pleural infection.
Does serum procalcitonin provide greater diagnostic
utility over white cell count and C-reactive protein in the
diagnosis of pleural infection?
The main objective of the study was to assess whether
PCT had a greater diagnostic utility over WCC and CRP
for the identification of pleural infection. Pleural infection
Table 1 Patient characteristics for 508 patients recruited to study between March 2008 and June 2013
Patients included in analysis
(n = 425)
Patients excluded from analysis
for incomplete data (n = 76)
Patients excluded from analysis
for no definitive diagnosis
(n = 7)
Male:female 283:142 (67:33%) 51:25 (67:33%) 7:0 (100:0%)
Median age (IQR) 72 (63–80) 75 (69–78) 81 (55.5–88.5)
Inpatient:outpatient 179:246 (42:58%) 36:39 (1 data not available) (47:51%) 5:2 (71:29%)
Diagnosis Metastatic malignancy 169 (39.8%) 32 (42.1%) –
Pleural infection 80 (18.8%) 11 (14.5%) –
Malignant mesothelioma 70 (16.5%) 4 (5.3%) –
Congestive cardiac failure 41 (9.6%) 7 (9.2%) –
BAPE 17 (4.0%) 6 (7.9%) –
Inflammatory pleuritis 13 (3.1%) 7 (9.2%) –
Pleural TB 10 (2.4%) 0 –
Other 25 (5.9%) 9 (11.8%) –
Diagnoses classed as “Other” included; renal failure, hepatic hydrothorax, pulmonary embolism, iatrogenic, trauma, drug-induced, connective tissue disease, post
coronary artery bypass graft, pancreatitis and Meigs syndrome
Abbreviations: BAPE benign asbestos related pleural effusion, IQR interquartile range, TB tuberculosis
Fig. 1 Flow chart showing the selection of patients for inclusion in
the study
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was diagnosed in 80/425 patients. 40 patients were diag-
nosed following a computerised tomography (CT) scan in
keeping with infection with radiological resolution follow-
ing treatment with antibiotics, 23 patients had a pleural
fluid pH < 7.2 and clinical presentation suggestive of sep-
sis, 10 patients with pleural infection had positive pleural
fluid microbiology, 6 patients had frank pus on pleural as-
piration and 1 patient was diagnosed on histology.
32/345 patients without a primary diagnosis of pleural
infection had an infection which was not considered to
be the primary cause of unilateral pleural effusion. Of
these 22 patients had pneumonia (contralateral or not
temporally related to the effusion), 6 patients had a urin-
ary tract infection, 1 patient had ophthalmic shingles, 1
patient had overwhelming sepsis of no clear source, 1
patient had a septic joint and 1 patient had a sub-
phrenic abscess. Those patients with a co-existing infec-
tion were excluded from analysis. ROC curve analysis
showed PCT, WCC and CRP had an area under the curve
(AUC) of 0.77 (95% CI = 0.71–0.84), 0.77 (95% CI = 0.71–
0.83) and 0.85 (0.80–0.90) respectively for identifying pa-
tients with pleural infection (Fig. 2). Procalcitonin did not
exhibit diagnostic characteristics superior to either WCC
or CRP (Table 3).
24/425 patients had a low CRP (<46.5 mg/l) and a low
WCC (<10.35 × 109/L) and a high PCT ≥0.085 μg/l.
Two/twenty-four of these patients had a diagnosis of
pleural infection. The causes of effusion in the remaining
patients were metastatic malignancy (6), congestive car-
diac failure (6), renal failure (3), inflammatory pleuritis (2),
BAPE (1), hepatic hydrothorax (1), malignant mesotheli-
oma (1) iatrogenic (1) and pleural tuberculosis (1). 1 pa-
tient had a concurrent urinary tract infection.
Does the use of antibiotics prior to presentation
significantly affect the diagnostic utility of procalcitonin,
white cell count and C-reactive protein?
Eighty patients had a 12-month diagnosis of pleural in-
fection and of these 56 patients had received antibiotics
prior to presentation to the pleural service, 17 patients
had no prior antibiotics and data was unavailable in 7
cases. The duration of antibiotic use is outlined in Fig. 3.
There was no statistically significant difference between
PCT (p = 0.80), WCC (p = 0.16) and CRP (p = 0.56) in the
patient group who received antibiotics and those who did
not (Additional file 3: Additional dataset 1). Furthermore
there was no significant statistical difference between
those who received antibiotics for ≥7 days and those who
did not receive antibiotics (p = 0.48).
Does procalcitonin provide relevant prognostic
information in pleural infection?
Patient outcomes and interventions were recorded for
80 cases of pleural infection. 27 patients required no
chest drain, 37 patients required a chest drain alone
and 16 patients required thoracic surgery. The me-
dian and interquartile range of PCT, CRP and WCC
for patients who required no chest drain, chest drain
alone or thoracic surgery can be found in Fig. 4 as a
dot plot.
Table 2 Twelve-month diagnosis of 425 patients presenting with unilateral pleural effusion between 2008 and 2013 and the
median and interquartile range of serum procalcitonin, white cell count and C-reactive protein
Diagnosis n % Procalcitonin (μg/l) White cell count (×109/L) C-reactive protein (mg/l)
Metastatic malignancy 169 39.8% <0.05 (0–0.12) 8.9 (7.4–11.0) 34.5 (12–90.75)
Pleural infection 80 18.8% 0.2 (0.1–0.7) 12.5 (9.2–16.3) 135.3 (71.6–239.6)
Malignant mesothelioma 70 16.5% <0.05 (<0.05- < 0.05) 8.7 (7.1–9.7) 22.2 (9.5–70.3)
Congestive cardiac failure 41 9.6% <0.05 (<0.05–0.1) 7.4 (6.2–9.2) 9.0 (5.1–22.6)
BAPE 17 4.0% <0.05 (<0.05–0.1) 8.5 (7.5–9.4) 27.0 (15.4–53.0)
Inflammatory pleuritis 13 3.1% <0.05 (<0.05–0.1) 7.1 (6.3–7.9) 10.0 (5.0–48.0)
Pleural TB 10 2.4% 0.1 (<0.05–0.2) 7.1 (6.9–7.5) 76.5 (36.9–111.7)
Renal failure 6 1.4% 0.1 (0.1–0.2) 6.8 (5.8–10.3) 25.0 (20.8–37.3)
Hepatic hydrothorax 4 0.9% <0.05 (<0.05–0.1) 5.0 (4.2–7.5) 2.0 (2.0–4.7)
Pulmonary embolism 3 0.7% <0.05 (n/a) 5.8 (n/a) 14.0 (n/a)
Iatrogenic/Trauma 3 0.7% <0.05 (n/a) 10.4 (n/a) 32 (n/a)
Connective tissue disease 3 0.7% <0.05 (n/a) 9.0 (n/a) 29.0 (n/a)
Post-CABG 3 0.7% <0.05 (n/a) 7.6 (n/a) 3.0 (n/a)
Pancreatitis 2 0.5% <0.05 (n/a) 4.0 (n/a) 19.0 (n/a)
Drug-induced 1 0.2% <0.05 (n/a) 8.6 (n/a) 13 (n/a)
Abbreviations: BAPE benign asbestos related pleural effusion, CABG coronary artery bypass graft, IQR interquartile range, TB tuberculosis
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ROC curve analysis showed PCT, WCC and CRP had
an AUC (95% CI) of 0.65 (0.48–0.83), 0.60 (0.44–0.76)
and 0.69 (0.54–0.85) respectively for the ability to pre-
dict the need for surgical intervention vs chest drain or
no intervention (Additional file 4: ROC curve analysis of
PCT, WCC and CRP for the ability to predict the need
for surgical intervention vs chest drain or no interven-
tion in patients with pleural infection). PCT did not
show greater prognostic ability than CRP and WCC for
the identification of patient who required thoracic sur-
gery (See Additional file 3: Additional dataset 2).
Procalcitonin >1.01 μg/l showed a sensitivity, specifi-
city, positive predictive value and negative predictive
value of 0.50, 0.88, 0.50 and 0.88 respectively for the
identification of those patients who would require surgi-
cal intervention.
12/80 patients died within 1 year of presentation with
pleural infection. 3/12 patients had a known malignancy
not thought to be the primary cause of their unilateral
pleural effusion and 4 patients had significant co-
morbidities including atrial fibrillation, ischaemic heart
disease and heart failure. Procalcitonin (p = 0.92), WCC
(p = 0.50) and CRP (p = 0.17) were not significantly
higher in the group of patients who died within 1 year of
presentation.
Is procalcitonin superior to white cell count and
C-reactive protein biomarkers in identifying patients with
malignancy and a co-existing pleural infection?
Two-hundred and thirty nine patients with a 12-month
diagnosis of pleural malignancy were analysed (malig-
nant mesothelioma or metastatic malignancy) to assess
whether PCT could accurately predict the presence of
co-existing infection. 23/239 patients presented with a
concurrent bacterial infection; 18 with pneumonia, 3
with a UTI, 1 with sepsis and 1 with ophthalmic shingles
Table 3 The sensitivity, specificity, positive predictive value and negative predictive value of PCT, WCC and CRP in the diagnosis of
pleural infection
Serum biomarker Sensitivity Specificity Positive
predictive
value
Negative
predictive
value
Positive
likelihood
ratio
Negative
likelihood
ratio
PCT AUC calculated optimal cut-off value ≥0.085 μg/l 0.69 0.80 0.46 0.91 3.36 0.39
Manufacturers recommended cut-off value ≥0.05 μg/l 0.78 0.66 0.37 0.92 2.27 0.34
WCC AUC calculated optimal cut-off value ≥10.35x109/L 0.69 0.80 0.46 0.91 3.36 0.39
CRP AUC calculated optimal cut-off value ≥46.5 mg/l 0.88 0.67 0.41 0.95 2.69 0.19
Abbreviations: AUC area under the curve, CRP C reactive protein, PCT procalcitonin, WCC white cell count
Fig. 2 ROC curve to show the ability of serum procalcitonin, white cell count and C-reactive protein to distinguish infective vs non-infective
causes of unilateral pleural effusion
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with bacterial infection. ROC curve analysis for the abil-
ity of PCT, WCC and CRP to predict the presence of
concurrent bacterial infection showed an AUC (95% CI)
of 0.68 (0.56–0.80), 0.68 (0.55–0.80) and 0.64 (0.50–
0.77) respectively (Additional file 5: ROC curve analysis
of PCT, WCC and CRP for the ability to predict pres-
ence of co-existing bacterial infection in patients pre-
senting with unilateral pleural effusion secondary to
malignancy). There was no statistically significant differ-
ence between PCT for those patients with or without a
Fig. 3 The effect of prior use of antibiotics on the diagnostic utility of procalcitonin in 80 patients presenting to the pleural service with
pleural infection
Fig. 4 Dot plots showing median and IQR of PCT, WCC and CRP in patients who received no intervention, chest drain insertion or thoracic
surgery for pleural infection. Outlier values; * 7.5, 14.68, ** 7.55, 45.49, *** 62.0. CRP = C-reactive protein, IQR = Interquartile range, PCT = Procalcitonin,
WCC =White cell count
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co-existing bacterial infection (Table 4). WCC and CRP
were significantly increased in patients with a co-
existing infection. PCT showed no significant greater
diagnostic utility over WCC or CRP for ability to distin-
guish between those patients with pleural malignancy
and co-existing infection and those without co-existing
infection (See Additional file 3: Additional dataset 3).
Discussion
This trial is the largest prospective analysis of serum
PCT measurement in patients presenting with unilateral
pleural effusions. We have demonstrated that PCT when
measured in all patients presenting with unilateral
pleural effusion to a tertiary pleural service offers no
greater diagnostic utility than WCC or CRP. Further-
more we have found that PCT has no significant prog-
nostic value in pleural infection in terms of predicting
1 year mortality or need for thoracic surgical interven-
tion. CRP and WCC were significantly higher in patients
with pleural malignancy who had a co-existing bacterial
infection.
Procalcitonin is a peptide precursor for calcitonin
which is released by the C-cells of the thyroid gland.
Under normal conditions levels of circulating procalcito-
nin are negligible. Procalcitonin has been studied in a
number of scenarios where it has been presented as a
test for distinguishing between bacterial infection and
other inflammatory insults [8]. Procalcitonin can distin-
guish between bacterial and aseptic meningitis, identify
infectious vs non-infectious exacerbations of chronic ob-
structive pulmonary disease (COPD) and help predict
aetiology and outcome in community acquired pneumo-
nia [9, 12–14]. Procalcitonin has been studied in pleural
disease both in the pleural fluid and serum however this
is the first study to attempt to characterise the role of
serum PCT as an immediate “bed-side” test in all
patients presenting with an undiagnosed unilateral
effusion.
Signs of pleural infection and pleural inflammation
can often be similar and can pose diagnostic difficulties.
Commonly used biomarkers such as CRP and WCC are
markers of inflammation and can be raised indiscrimin-
ately in pro-inflammatory states such as malignancy and
infection [10]. Previously pleural fluid PCT has been
shown to be inferior to a range of other markers in dis-
tinguishing between infected and non-infected effusions
as well as being inferior to serum PCT [6, 7, 15, 16].
Serum PCT studies have suggested that higher values
could be a useful indicator of pleural infection, however
only specifically selected small numbers of patients
(<100) have been studied [15]. McCann et al. addressed
the issue of inflammation vs infection by comparing
PCT and CRP levels before and after a sterile inflamma-
tory insult (talc pleurodesis). The study found that whilst
CRP rose significantly (360%) the rise in PCT was less
marked (21%); however, this is just one cause of non-
infective inflammation and it is yet to be determined
whether malignant processes have the same effect on
PCT.
We analysed serum PCT, WCC and CRP in consecu-
tive patients presenting to our tertiary referral centre
prospectively recruited to a pleural study. Procalcitonin
has previously been presented as a marker of infection
which can be used to guide the duration of antibiotic
therapy [17, 18]. Therefore it was predicted that anti-
biotic therapy may reduce the ability of PCT to identify
infection. In our cohort, 68% of patients (56/80) with
pleural infection had received antibiotics in the 2 weeks
preceding presentation. We have shown that the use of
antibiotics did not significantly affect the diagnostic util-
ity of procalcitonin. It could be suggested that a longer
duration of antibiotics (≥7 days) prior to investigation
could theoretically hinder the diagnostic ability of pro-
calcitonin. However, we have shown no statistically sig-
nificant difference in procalcitonin between those
patients who received ≥7 days of antibiotics and those
who received none (p = 0.48).
The diagnostic ability of PCT in the presence of renal
failure has not been conclusively verified. Previous stud-
ies have suggested that renal function may interfere with
PCT values [19, 20]. We found patients with unilateral
pleural effusions secondary to renal failure with no evi-
dence of infection had raised levels of PCT (Table 2).
However, only 6 patients were diagnosed with a unilat-
eral pleural effusion secondary to renal failure. Further
studies are required to assess the relationship between
renal failure and PCT in patients with unilateral pleural
effusions.
Predicting outcome in pleural infection is difficult, it
has previously been shown there are no reliable clinical,
pleural fluid or radiological characteristics that will pre-
dict failure of medical therapy upon admission [21]. One
of the key diagnostic questions is how to identify those
patients who require invasive intervention such as
pleural drainage or thoracic surgery. Persistently high in-
flammatory markers such as CRP and WCC have been
shown to be associated with poorer outcomes and the
Table 4 Median and IQR of PCT, WCC and CRP for patients with
pleural malignancy with and without a co-existing bacterial
infection
Co-existing
infection
No co-existing
infection
p-value
N 23 216 –
PCT (Median (IQR)) μg/l 0.11 (<0.05–0.15) <0.05 (<0.05–0.08) 0.75
WCC (Median (IQR)) ×109/L 10.0 (8.5–20.3) 8.7 (7.2–10.2) 0.004
CRP (Median (IQR)) mg/l 88.3 (11.4–135.8) 29.0 (11.0–81.5) 0.0003
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need to perform chest tube drainage [22]. Around 30%
of patients can be expected to need thoracic surgery or
die as a result of pleural infection [23]. Currently, there
is no defined criteria for surgical intervention in pleural
infection and the decision to operate remains subjective
[1]. Our study has shown no statistically significant dif-
ference in PCT, WCC and CRP between patients who
required no intervention, chest tube drainage or thoracic
surgery. This is in line with previously reported conclu-
sion using the Multicentre Intra-pleural Sepsis Trial
(MIST) data [5]. Fig. 4 does show a strong trend be-
tween PCT and degree of intervention required and in-
creased sample size may allow sufficient power to
identify a statistically significant difference.
Unilateral pleural effusions can have dual pathology
with a number of processes contributing to the accumu-
lation of fluid. Pleural malignancy may be complicated
by either intra- or extra-thoracic infection. Identifying
those patients who may require antibiotics despite a pri-
mary malignant process could improve short-term out-
comes. Approximately 10% (23/239) of patients with a
diagnosis of malignant unilateral pleural effusion also
had a co-existing infection at presentation. Our data
shows PCT has no significant greater diagnostic utility
over WCC or CRP in identifying patients who have
pleural infection alongside a malignant process. Further-
more CRP and WCC were found to be significantly
higher in patients with a co-existing bacterial infection
(p = 0.004 and p = 0.0003 respectively).
Limitations
There are limitations to the current study. The study ini-
tially investigated the role of PCT in all patients present-
ing to a pleural service and then focussed on specific
subsets of patients. Whilst the current study failed to
identify a specific subset where PCT out-performed
WCC and CRP there may be subsets not yet analysed
who may benefit from serum PCT analysis. Further stud-
ies to specifically select patients at presentation who
may benefit from PCT measurement could identify a
diagnostic role for serum PCT.
The analysis was intended to look at the diagnostic
capabilities in all patients attending the pleural service
however 76/508 patients were excluded because of insuf-
ficient storage of sample fluid. There were 7 patients ex-
cluded from the trial due to no definitive diagnosis.
Further investigation of these patients was not carried
out due to clinical resolution of symptoms. The number
of patients not consenting to trial inclusion was not re-
corded. The gold standard for the diagnosis of pleural
infection is positive pleural fluid microbiology. In our
study 10/80 (12.5%) patients had positive pleural fluid
microbiology, this is lower than reported culture positive
rates and may be because of the high numbers of
patients who had received antibiotics prior to their pres-
entation to our tertiary centre [23, 24]. Therefore in
order to diagnose infection we relied upon other clas-
sical markers such as low pleural fluid pH. Further study
of patients with culture-positive pleural infection is re-
quired to validate the results.
Pleural effusion may also be caused by viral infection
[25]. Procalcitonin is a poor diagnostic marker of viral
infection and therefore may partly explain the current
findings.
The study was conducted at a single centre, and the
results may not be representative of patient subgroups
in other healthcare settings, particularly with respect
to decision-making around invasive procedures and
surgery specifically, the thresholds for which may vary
internationally.
In our study PCT was only measured at one time
point (at initial presentation). Previous studies in non-
pleural disease have used procalcitonin as a biomarker
to decide when to stop antibiotic therapy [17, 18]. The
role of PCT in monitoring response to treatment was
not assessed by the current study.
The measurement of serum PCT was performed on
frozen stored samples of serum. We were unable to
guarantee the samples had not been altered through the
storage process. The study design meant that the investi-
gators and clinicians were not blinded to CRP or WCC
during treatment and diagnosis and these values may
have influenced decisions on management and specific-
ally thoracic surgery. Furthermore, the CRP and WCC
may have influenced the definitive consultant diagnosis
thus overestimating the diagnostic accuracy of CRP and
WCC. The PCT value, however, was not available during
investigation, treatment or diagnosis.
Procalcitonin has previously been used as a marker of
systemic infection [8]. The intention of the study was to
assess the diagnostic utility of PCT in pleural infection
rather than its use as a marker of systemic infection. It
is possible that PCT failed to outperform traditional bio-
markers because compartmentalised pleural infection
has a reduced effect on serum PCT.
To prevent analysis of patients with raised PCT due to
non-pleural infection we excluded patients with infec-
tions that were not the primary cause of the unilateral
pleural effusion from our analysis. However in practice
the location of infection may not always be apparent at
presentation and as such further targeted investigations
are always required.
Our study attempted to analyse the effect of the prior
use of antibiotics on the diagnostic capabilities of PCT.
The study was limited as just 17 patients received no an-
tibiotics prior to presentation. It is likely that PCT re-
sponds to antibiotics in 24–48 h and therefore further
analysis should be carried out on patients who had
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received <48 h of antibiotics. The current dataset would
have to be extended to confirm the relationship between
antibiotic use and serum PCT.
Conclusions
In summary this large study provides evidence that there
is no greater diagnostic utility in the routine use of
serum PCT in adult patients presenting with unilateral
pleural effusions. No additional diagnostic utility was
found when using procalcitonin over CRP and WCC in
identifying bacterial pleural infection. The current study
also suggests PCT also offers no significant prognostic
information in pleural infection with respect to predict-
ing the need for surgery or mortality. This study should
discourage the routine use of serum PCT all patents pre-
senting with unilateral pleural effusion. However further
studies may identify specific subsets of patients who may
benefit from PCT measurement.
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